Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The use of monoclonal antibodies to treat mesothelioma

ELCC 2010

28 Apr - 1 May 2010

Published: 8 Jun 2010

Views: 8728

Rating:

Save

Prof Jan van Meerbeeck - University Hospital, Ghent, Belgium

Prof Jan van Meerbeeck, discuses his research into the use of monoclonal antibodies to treat mesothelioma, a disease generally seen in professionally exposed individuals. Professor van Meerbeeck speaks about the future of lung cancer treatment and predicts a greater emphasis on individualised and targeted treatments.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC

Dr Edgardo Santos - Florida Precision Oncology, Florida, USA

Immunotherapy developments and new agents for locally advanced NSCLC and SCLC ( Dr Edgardo Santos - Florida Precision Oncology, Florida, USA )

Predictive and prognostic biomarkers for immunotherapy in lung cancer

Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Predictive and prognostic biomarkers for immunotherapy in lung cancer ( Dr Ignacio Gil Bazo - Fundación Instituto Valenciano de Oncología (FIVO), Valencia, Spain )

ASCO 2023: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ASCO 2023: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

LUMINANCE: Results support use of durvalumab and platinum-etoposide for...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1...

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona...

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC ( Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

WCLC 2022: Highlights

Dr Luis Raez - Memorial Cancer Institute, Florida, USA

WCLC 2022: Highlights ( Dr Luis Raez - Memorial Cancer Institute, Florida, USA )

More from ecancer